Skip to main content

For people 2 years of age and older with active psoriatic arthritis

COSENTYX can help with unpredictable psoriatic arthritis symptoms.

The first and only treatment to offer both self-injection and IV infusion dosing options that target IL-17A.*

Want to learn more about taking COSENTYX?

*For adults.

Results fast. Relief that can last.

COSENTYX is proven to help reduce symptoms of psoriatic arthritis (PsA).

3 WEEKS, 5 YEARS, #1 PRESCRIBED:

  • COSENTYX can start working in as little as 3 weeks for psoriatic arthritis symptoms.

  • For patients who continued COSENTYX for 5 years, a similar percentage saw an improvement in psoriatic arthritis symptoms.§

  • COSENTYX® is the #1 prescribedand first biologic treatment of its kind.#

All results shown from clinical trials using subcutaneous (under the skin) injection. The FDA approval of the intravenous (IV) administration (injected into a vein) of COSENTYX is based on data showing that the amount of the medication in your body after it is given directly through IV was within the range that would be seen when given as SC.
Up to 60% of patients in a clinical trial saw at least a 20% improvement in psoriatic arthritis symptoms at 16 weeks versus 18% of patients taking placebo.
§In this study, the medication being used was revealed to doctors and patients after 1 year, which may affect the results.
Across all indications
#Treatment for PsA that targets IL-17A, one of the multiple molecules in the body that may play a role in inflammation.

Jordan is an actual COSENTYX patient.

Individual results may vary. Jordan was compensated for her time.

“I feel better. COSENTYX helps me keep moving.”

– Jordan, actual patient

Experiencing unpredictable psoriatic arthritis symptoms?

Psoriatic arthritis symptoms can be unpredictable. See how COSENTYX can help treat the multiple symptoms of psoriatic arthritis.

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.